Proteomic patterns of tumour subsets in non-small-cell lung cancer

Yanagisawa, Kiyoshi; Shyr, Yu; Xu, Baogang; Massion, Pierre P.; Larsen, Paul H; White, Bill C.; Roberts, John R.; Edgerton, Mary E.; González, Adriana; Nadaf, Sorena; Moore, Jason H.; Caprioli, Richard M.; Carbone, David P.

doi:10.1016/s0140-6736(03)14068-8

Cited by 579 publications

(488 citation statements)

References 28 publications

Supporting

Mentioning

473

Contrasting

Unclassified

Order By: Relevance

“…MALDI profiling and imaging has already been successfully applied to samples ranging from individually captured cells [11,12], to intact organs, and whole animal sagittal sections [1]. Although a relatively young method, tissue analysis by imaging mass spectrometry (IMS) has been used to address a number of clinical questions in cancer [13,14], neurodegenerative diseases [15][16][17], organ development [18] and the study of drug and metabolite distribution [19][20][21]. Due to the variety of applications and the potential of tissue analysis by MALDI mass spectrometry to offer solutions directed at difficult problems in diagnostic and prognostic medicine, tissue profiling and imaging will continue to be an important topic of research.…”

Section: Introductionmentioning

confidence: 99%

“…Raw spectra are conditioned through the removal of background, normalization of intensity, and alignment. The analytical goals of profiling experiments can be two-fold: (1) the classification of samples into two or more classes such as diseased/non-diseased in order to better aid patients' care [22][23][24], and (2) the identification of biomarkers characteristic to each class [13,14]. Identification of disease specific proteins could yield mechanistic information as well as potential diagnostic markers or drug targets.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Processing MALDI mass spectra to improve mass spectral direct tissue analysis

Norris¹,

Cornett

Mobley

et al. 2007

International Journal of Mass Spectrometry

196

188

View full text Add to dashboard Cite

Profiling and imaging biological specimens using MALDI mass spectrometry has significant potential to contribute to our understanding and diagnosis of disease. The technique is efficient and high-throughput providing a wealth of data about the biological state of the sample from a very simple and direct experiment. However, in order for these techniques to be put to use for clinical purposes, the approaches used to process and analyze the data must improve. This study examines some of the existing tools to baseline subtract, normalize, align, and remove spectral noise for MALDI data, comparing the advantages of each. A preferred workflow is presented that can be easily implemented for data in ASCII format. The advantages of using such an approach are discussed for both molecular profiling and imaging mass spectrometry.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Processing MALDI mass spectra to improve mass spectral direct tissue analysis

Norris¹,

Cornett

Mobley

et al. 2007

International Journal of Mass Spectrometry

196

188

View full text Add to dashboard Cite

show abstract

“…A high-throughput proteomic approach combined with an in vitro carcinogenesis cell model and tissue immunoassay analysis identified changes in proteins associated with sequential pathogenesis of non-small cell lung cancer (NSCLC) (18). We reported proteomic patterns specific for normal alveolar and normal bronchial tissues, preinvasive lesions, and invasive lung cancer tissues (19,20). The proteomic profiles obtained by matrixassisted laser desorption ionization mass spectrometry (MALDI MS) of normal lung, preinvasive lesions, of the lung and invasive lung cancer tissues were able to cluster these three groups in a continuum based on 38 discriminatory features (molecular weight signatures expressed as mass-to-charge ratios, m/z) .…”

Section: Analysis Of Preinvasive Lesions For Risk Assessment Biomarkersmentioning

confidence: 99%

Advances in Proteomic Strategies toward the Early Detection of Lung Cancer

Hassanein¹,

Rahman²,

Chaurand³

et al. 2011

Proceedings of the American Thoracic Society

View full text Add to dashboard Cite

TennesseeSince the advent of the new proteomics era more than a decade ago, large-scale studies of protein profiling have been exploited to identify the distinctive molecular signatures in a wide array of biological systems spanning areas of basic biological research, various disease states, and biomarker discovery directed toward therapeutic applications. Recent advances in protein separation and identification techniques have significantly improved proteomics approaches, leading to enhancement of the depth and breadth of proteome coverage. Proteomic signatures specific for invasive lung cancer and preinvasive lesions have begun to emerge. In this review we provide a critical assessment of the state of recent advances in proteomic approaches and the biological lessons they have yielded, with specific emphasis on the discovery of biomarker signatures for the early detection of lung cancer.Keywords: proteomics; biomarker; early detection; lung cancer CHALLENGES IN LUNG CANCER RESEARCHLung cancer is the deadliest cancer in the United States and worldwide, accounting for 15% of all cancer incidence and 29% of all cancer deaths, with a 5-year survival rate of only 15% (1, 2). Lung cancer represents a spectrum of diseases with tremendous heterogeneity at the pathological and molecular levels (3-6) that is strongly associated with smoking as a risk factor. With about 20% of the United States adult population smoking and 1 billion smokers worldwide, it was estimated that in 2009 lung cancer claimed more lives than breast, prostate, colon, liver, kidney, and melanoma cancers combined (2, 7). Despite the recent improvements of bronchoscopic and surgical techniques as well as advances in chemotherapy and radiation therapy treatments, attempts to improve patient outcomes are faced with immense challenges. Several noninvasive detection technologies have been investigated. Imaging techniques, such as chest radiography, lowdose spiral computed tomography, sputum cytology, and molecular biomarkers in various biological samples, have been tested for their diagnostic value for early detection of lung cancer (8, 9). Although these tests vary in their sensitivity and specificity, only low-dose chest computed tomography was shown to reduce lung cancer-specific mortality (10-12). This encouraging finding calls for new molecular strategies to address the noninvasive diagnostic and risk assessment for lung cancer. These molecular strategies will have to demonstrate clinical utility and may complement currently tested strategies. NATURAL HISTORY OF LUNG CANCER PROGRESSION AND A WINDOW FOR EARLY DETECTIONLung cancer can be considered to result from a long history of repeated airway damage and repair cycles. Although clinically addressed at the time of diagnosis, the disease process develops for months and years before affecting patients' lives. This rather long disease process (Figure 1) represents a window of opportunity where the intervention should take place with the aim of preventing the development of disease (e.g., primary preven...

show abstract

“…The Eastern Cooperative Oncology Group 3503 study showed that a prediction algorithm incorporating matrix-assisted laser desorption/ionization (MALDI) mass spectrometry facilitated the selection of a subset of patients with NSCLC who were likely to benefit from a first-line treatment with erlotinib (Solomon et al, 2007). Proteomics has also shown potential for defining pathological differences in subsets of patients with lung cancer (Yanagisawa et al, 2003), and has been suggested as a potential tool for the early identification of lung cancer (Conrad et al, 2008).…”

Section: Proteomicsmentioning

confidence: 99%

Individualized therapy in non-small-cell lung cancer: future versus current clinical practice

Pérez-Soler

2009

Oncogene

View full text Add to dashboard Cite

Proteomic patterns of tumour subsets in non-small-cell lung cancer

Cited by 579 publications

References 28 publications

Processing MALDI mass spectra to improve mass spectral direct tissue analysis

Processing MALDI mass spectra to improve mass spectral direct tissue analysis

Advances in Proteomic Strategies toward the Early Detection of Lung Cancer

Individualized therapy in non-small-cell lung cancer: future versus current clinical practice

Contact Info

Product

Resources

About